These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6776192)

  • 21. Role of cytostasis in antitumor immunity against syngeneic X5563 plasmocytoma: comparative study of cytostasis and cytolysis using variant tumors and neonatally thymectomized mice.
    Mitani M; Himeno K; Mori K; Nomoto K
    J Clin Lab Immunol; 1989 May; 29(1):45-52. PubMed ID: 2628584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies in the enhancement of tumour immunity by coupling strong antigens to tumour cells ('heterogenization of tumours'). Helper T cell clones against PPD help other T cells mount anti-tumour responses to PPD-coupled tumour cells.
    Sia DY; Lachmann PJ; Leung KN
    Immunology; 1984 Apr; 51(4):755-63. PubMed ID: 6200428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The augmentation of tumor-specific immunity by T-T cell interaction].
    Fujiwara H; Takai Y; Fukuzawa M; Yoshioka T; Izumi Y; Mizushima Y; Qian J; Ogata M; Kosugi A; Nakajima H
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):734-40. PubMed ID: 3157349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
    Kurata S; Tsuchiya T; Norimura T; Yamashita U
    J Immunol; 1983 Jan; 130(1):496-500. PubMed ID: 6600195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of antibody response in different immunoglobulin classes. I. Selective suppression of anti-DNP IgE antibody response by preadministration of DNP-coupled mycobacterium.
    Kishimoto T; Hirai Y; Suemura M; Yamamura Y
    J Immunol; 1976 Aug; 117(2):396-404. PubMed ID: 820800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.
    Sato S; Fujiwara H; Kosugi A; Hamaoka T
    Cancer Immunol Immunother; 1987; 24(2):121-6. PubMed ID: 3493845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mechanism of specific suppression in effector T cell clones against tumor-associated transplantation antigens.
    Fujiwara H; Tsuchida T; Mizuochi T; Kohmo T; Hamaoka T
    Gan; 1981 Oct; 72(5):732-41. PubMed ID: 7035282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerance induction in tumor-specific effector T cells by presensitization with tumor antigens via the intragastric route.
    Hashimoto T; Okuno K; Tsuchida T; Fujiwara H; Hamaoka T
    Gan; 1984 Jul; 75(7):610-6. PubMed ID: 6236126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
    Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-specific suppressor cells induced by immunization with spleen cells from tumor-bearing animals.
    Huber SA; Bigi G; Lucas ZJ
    Cancer Res; 1980 Oct; 40(10):3477-83. PubMed ID: 6449281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of murine cytokine responses to mycobacterial antigens by helminth-induced T helper 2 cell responses.
    Pearlman E; Kazura JW; Hazlett FE; Boom WH
    J Immunol; 1993 Nov; 151(9):4857-64. PubMed ID: 8409444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Splenic immune effector and suppressor cells in mice bearing a growing plasmacytoma.
    Chen YH; Anderson AB; Williams KG
    Cancer Res; 1985 Nov; 45(11 Pt 1):5473-9. PubMed ID: 2932218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses.
    Uekusa Y; Gao P; Yamaguchi N; Tomura M; Mukai T; Nakajima C; Iwasaki M; Takeuchi N; Tsujimura T; Nakazawa M; Fujiwara H; Hamaoka T
    J Leukoc Biol; 2002 Nov; 72(5):864-73. PubMed ID: 12429708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T-lymphocyte activities by suppressor T-cell-depleted hapten-reactive T lymphocytes.
    Hamaoka T; Fujiwara H; Teshima K; Aoki H; Yamamoto H; Kitagawa M
    J Exp Med; 1979 Jan; 149(1):185-99. PubMed ID: 310858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
    Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism].
    Kosugi A; Fujiwara H; Hamaoka T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1527-35. PubMed ID: 6236750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.
    Shimizu M; Yamamoto A; Nakano H; Matsuzawa A
    Cancer Res; 1996 Aug; 56(16):3731-6. PubMed ID: 8706016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.